Virax Biolabs
VRAX
4 hedge funds and large institutions have $72.4K invested in Virax Biolabs in 2026 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, reducing their positions, and 0 closing their positions.
100% more funds holding
Funds holding: 2 → 4 (+2)
0.85% more ownership
Funds ownership: 3.31% → 4.16% (+0.85%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$19.5K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$755 |
| 3 |
Caitong International Asset Management
Hong Kong
|
+$9 |
| 4 |
JP Morgan Chase
New York
|
+$6 |
Top Sellers
VRAX Hedge Fund Activity: Q3 2026 in Review
4 of the 8,227 institutional investors tracked by Wall St. Rank reported a position in Virax Biolabs (VRAX) for Q3 2026, worth a combined $72.4K — down 6.6% from $77.6K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new VRAX positions and 0 closed out — a net gain of 2 holders — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Jane Street, adding an estimated $19.5K.
- 4 institutional investors held Virax Biolabs (VRAX) as of Q3 2026, up from 2 in Q2 2026.
- Funds reported $72.4K of Virax Biolabs stock for Q3 2026, down 6.6% quarter-over-quarter.
- 2 funds opened new Virax Biolabs positions in Q3 2026 and 0 closed out, a net change of +2 holders.
- The largest Virax Biolabs buyer in Q3 2026 was Jane Street, an estimated $19.5K added.
Based on aggregated 13F filings for Q3 2026.